AAAAAA

   
Results: 1-25 | 26-50 | 51-63
Results: 26-50/63
Model aims to reduce discrepancy between phase II, phase III trials
Authors: Reynolds, T
Citation: T. Reynolds, Model aims to reduce discrepancy between phase II, phase III trials, J NAT CANC, 92(19), 2000, pp. 1554-1556
How does a drug get to phase III trials?
Authors: Reynolds, T
Citation: T. Reynolds, How does a drug get to phase III trials?, J NAT CANC, 92(19), 2000, pp. 1555-1555
One gene, two genes, three genes, four: Scientists wonder how many more
Authors: Reynolds, T
Citation: T. Reynolds, One gene, two genes, three genes, four: Scientists wonder how many more, J NAT CANC, 92(17), 2000, pp. 1371-1373
Costs studies show clinical trials, standard therapy may be equal
Authors: Reynolds, T
Citation: T. Reynolds, Costs studies show clinical trials, standard therapy may be equal, J NAT CANC, 92(14), 2000, pp. 1116-1118
Antioxidants and cancer: What is the evidence?
Authors: Reynolds, T
Citation: T. Reynolds, Antioxidants and cancer: What is the evidence?, J NAT CANC, 92(13), 2000, pp. 1033-1034
Screening for Down's syndrome - A large independent trial would be useful
Authors: Reynolds, T
Citation: T. Reynolds, Screening for Down's syndrome - A large independent trial would be useful, BR MED J, 321(7263), 2000, pp. 764-764
Preventing pressure sores - More research is needed into the origins of pressure sores
Authors: Russell, L Reynolds, T Clark, M
Citation: L. Russell et al., Preventing pressure sores - More research is needed into the origins of pressure sores, BR MED J, 320(7237), 2000, pp. 802-802
An investigation into the use of serum albumin in pressure sore prediction
Authors: Anthony, D Reynolds, T Russell, L
Citation: D. Anthony et al., An investigation into the use of serum albumin in pressure sore prediction, J ADV NURS, 32(2), 2000, pp. 359-365
Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by Rac1 and phosphatidylinositol-3 kinase activation
Authors: Sanlioglu, S Benson, PK Yang, JS Atkinson, EM Reynolds, T Engelhardt, JF
Citation: S. Sanlioglu et al., Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by Rac1 and phosphatidylinositol-3 kinase activation, J VIROLOGY, 74(19), 2000, pp. 9184-9196
An evaluation of the synapse specificity of long-term depression induced in rat cerebellar slices
Authors: Reynolds, T Hartell, NA
Citation: T. Reynolds et Na. Hartell, An evaluation of the synapse specificity of long-term depression induced in rat cerebellar slices, J PHYSL LON, 527(3), 2000, pp. 563-577
Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial
Authors: Akriviadis, E Botla, R Briggs, W Han, S Reynolds, T Shakil, O
Citation: E. Akriviadis et al., Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial, GASTROENTY, 119(6), 2000, pp. 1637-1648
Camberwell Assessment of Need for the Elderly (CANE) - Development, validity and reliability
Authors: Reynolds, T Thornicroft, G Abas, M Woods, B Hoe, J Leese, M Orrell, M
Citation: T. Reynolds et al., Camberwell Assessment of Need for the Elderly (CANE) - Development, validity and reliability, BR J PSYCHI, 176, 2000, pp. 444-452
Ethics of placebo-controlled trials (vol 133, pg 491, 2000)
Authors: Reynolds, T
Citation: T. Reynolds, Ethics of placebo-controlled trials (vol 133, pg 491, 2000), ANN INT MED, 133(9), 2000, pp. 754-754
The ethics of placebo-controlled trials
Authors: Reynolds, T
Citation: T. Reynolds, The ethics of placebo-controlled trials, ANN INT MED, 133(6), 2000, pp. 491-492
Declining breast cancer mortality: What's behind it?
Authors: Reynolds, T
Citation: T. Reynolds, Declining breast cancer mortality: What's behind it?, J NAT CANC, 91(9), 1999, pp. 750-753
Cell death genes may hold clues to preserving fertility after chemotherapy
Authors: Reynolds, T
Citation: T. Reynolds, Cell death genes may hold clues to preserving fertility after chemotherapy, J NAT CANC, 91(8), 1999, pp. 664-666
Treating the most intractable cancers progresses slowly
Authors: Reynolds, T
Citation: T. Reynolds, Treating the most intractable cancers progresses slowly, J NAT CANC, 91(5), 1999, pp. 404-406
Cancer vaccine competition wide open as agents move rapidly into clinical arena
Authors: Reynolds, T
Citation: T. Reynolds, Cancer vaccine competition wide open as agents move rapidly into clinical arena, J NAT CANC, 91(4), 1999, pp. 309-312
Celebrity's death spurs interest in rare cancers
Authors: Reynolds, T
Citation: T. Reynolds, Celebrity's death spurs interest in rare cancers, J NAT CANC, 91(24), 1999, pp. 2070-2071
Advances in treatment for eye cancer bring visible benefits
Authors: Reynolds, T
Citation: T. Reynolds, Advances in treatment for eye cancer bring visible benefits, J NAT CANC, 91(21), 1999, pp. 1804-1805
A natural edge: Nature still offers the greatest drug diversity
Authors: Reynolds, T
Citation: T. Reynolds, A natural edge: Nature still offers the greatest drug diversity, J NAT CANC, 91(19), 1999, pp. 1608-1610
Charity volunteers face forward with a new look
Authors: Reynolds, T
Citation: T. Reynolds, Charity volunteers face forward with a new look, J NAT CANC, 91(18), 1999, pp. 1534-1536
New estrogen receptor adds complexity, recasts drug strategies
Authors: Reynolds, T
Citation: T. Reynolds, New estrogen receptor adds complexity, recasts drug strategies, J NAT CANC, 91(17), 1999, pp. 1445-1447
Why randomized surgical oncology trials are so scarce
Authors: Reynolds, T
Citation: T. Reynolds, Why randomized surgical oncology trials are so scarce, J NAT CANC, 91(14), 1999, pp. 1182-1183
Prevention study turns spotlight on bladder cancer
Authors: Reynolds, T
Citation: T. Reynolds, Prevention study turns spotlight on bladder cancer, J NAT CANC, 91(13), 1999, pp. 1102-1103
Risultati: 1-25 | 26-50 | 51-63